NL1010018C2 - Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. - Google Patents
Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. Download PDFInfo
- Publication number
- NL1010018C2 NL1010018C2 NL1010018A NL1010018A NL1010018C2 NL 1010018 C2 NL1010018 C2 NL 1010018C2 NL 1010018 A NL1010018 A NL 1010018A NL 1010018 A NL1010018 A NL 1010018A NL 1010018 C2 NL1010018 C2 NL 1010018C2
- Authority
- NL
- Netherlands
- Prior art keywords
- alkyl
- formula
- ethyl
- group
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97202762 | 1997-09-09 | ||
EP97202762 | 1997-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
NL1010018C2 true NL1010018C2 (nl) | 1999-03-10 |
Family
ID=8228716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL1010018A NL1010018C2 (nl) | 1997-09-09 | 1998-09-04 | Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. |
Country Status (9)
Country | Link |
---|---|
US (1) | US6350750B1 (fr) |
EP (1) | EP0966442B1 (fr) |
JP (1) | JP4276703B2 (fr) |
AT (1) | ATE348812T1 (fr) |
AU (1) | AU9624198A (fr) |
CA (1) | CA2270777C (fr) |
DE (1) | DE69836678T2 (fr) |
NL (1) | NL1010018C2 (fr) |
WO (1) | WO1999012908A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE250035T1 (de) * | 1997-04-22 | 2003-10-15 | Janssen Pharmaceutica Nv | Chinolin- und chinazolin-derivate als crf antagonisten |
US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
DE60026155T2 (de) | 1999-09-30 | 2006-08-10 | Neurogen Corp., Branford | Einige alkylendiamin-substituierte heterocyclen |
WO2001062718A1 (fr) * | 2000-02-25 | 2001-08-30 | Japan Tobacco, Inc. | Dérivé de benzamide et utilisation de celui-ci |
US6670362B2 (en) | 2000-09-20 | 2003-12-30 | Pfizer Inc. | Pyridazine endothelin antagonists |
NZ540612A (en) | 2003-01-14 | 2008-02-29 | Arena Pharm Inc | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
AU2004257267B2 (en) * | 2003-07-14 | 2009-12-03 | Arena Pharmaceuticals,Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
EP1656145A1 (fr) * | 2003-08-12 | 2006-05-17 | F. Hoffmann-La Roche Ag | Tetrahydroquinazolines spiro-substituees utilisees en tant qu'antagonistes du facteur de liberation de la corticotrophine (crf) |
CN100398524C (zh) * | 2003-08-12 | 2008-07-02 | 弗·哈夫曼-拉罗切有限公司 | 作为crf拮抗剂的四氢喹唑啉衍生物 |
WO2011094008A1 (fr) | 2010-01-27 | 2011-08-04 | Arena Pharmaceuticals, Inc. | Procédés de préparation d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclopenta]indol-3-yl) acétique et de ses sels |
EP2619198A1 (fr) | 2010-09-22 | 2013-07-31 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés |
EP4445956A2 (fr) | 2015-01-06 | 2024-10-16 | Arena Pharmaceuticals, Inc. | Composé pour le traitement des affections associés à s1p1-récepteur |
WO2016209809A1 (fr) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1 |
WO2018151873A1 (fr) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
EP3601267A1 (fr) | 2017-03-21 | 2020-02-05 | Bayer Pharma Aktiengesellschaft | 2-méthyl-quinazolines |
EP3781565A1 (fr) | 2018-04-18 | 2021-02-24 | Bayer Pharma Aktiengesellschaft | 2-méthyl-aza-quinazolines |
EP4223761A1 (fr) * | 2020-09-30 | 2023-08-09 | Shanghai Pharmaceuticals Holding Co., Ltd. | Composé quinazoline et son application |
CN117203207A (zh) * | 2021-04-30 | 2023-12-08 | 江苏恒瑞医药股份有限公司 | 桥环类化合物、其制备方法及其在医药上的应用 |
CN115504932B (zh) * | 2022-08-12 | 2024-01-26 | 河南师范大学 | 一种3-取代喹啉类化合物的合成方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ287613B6 (en) * | 1994-06-16 | 2001-01-17 | Pfizer | Pyrazolo- and pyrrolopyridines and pharmaceutical preparations based thereon |
PL191271B1 (pl) | 1996-02-07 | 2006-04-28 | Neurocrine Biosciences Inc | Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna |
TW477787B (en) * | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
WO1998029397A1 (fr) | 1996-12-27 | 1998-07-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes pyrimidine a anneaux condenses et leur utilisation medicinale |
WO1998035967A2 (fr) * | 1997-02-18 | 1998-08-20 | Neurocrine Biosciences, Inc. | Antagonistes de recepteurs du crf et procedes associes |
ATE250035T1 (de) * | 1997-04-22 | 2003-10-15 | Janssen Pharmaceutica Nv | Chinolin- und chinazolin-derivate als crf antagonisten |
-
1998
- 1998-09-04 NL NL1010018A patent/NL1010018C2/nl not_active IP Right Cessation
- 1998-09-07 WO PCT/EP1998/005726 patent/WO1999012908A1/fr active IP Right Grant
- 1998-09-07 AU AU96241/98A patent/AU9624198A/en not_active Abandoned
- 1998-09-07 EP EP98950008A patent/EP0966442B1/fr not_active Expired - Lifetime
- 1998-09-07 AT AT98950008T patent/ATE348812T1/de not_active IP Right Cessation
- 1998-09-07 DE DE69836678T patent/DE69836678T2/de not_active Expired - Lifetime
- 1998-09-07 JP JP51510099A patent/JP4276703B2/ja not_active Expired - Fee Related
- 1998-09-07 US US09/297,837 patent/US6350750B1/en not_active Expired - Lifetime
- 1998-09-07 CA CA002270777A patent/CA2270777C/fr not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2270777A1 (fr) | 1999-03-18 |
JP2001505226A (ja) | 2001-04-17 |
EP0966442B1 (fr) | 2006-12-20 |
ATE348812T1 (de) | 2007-01-15 |
AU9624198A (en) | 1999-03-29 |
WO1999012908A1 (fr) | 1999-03-18 |
DE69836678T2 (de) | 2007-04-05 |
US6350750B1 (en) | 2002-02-26 |
CA2270777C (fr) | 2008-04-22 |
DE69836678D1 (de) | 2007-02-01 |
EP0966442A1 (fr) | 1999-12-29 |
JP4276703B2 (ja) | 2009-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL1010018C2 (nl) | Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. | |
KR102366670B1 (ko) | O-아미노헤테로아릴알키닐기를 함유한 화합물 및 이의 제조 방법과 용도 | |
KR100256707B1 (ko) | 데아자푸린 유도체; 새로운 부류의 crf1 특이 리간드 | |
CN1315809C (zh) | 喹啉衍生物和其作为5-ht6配体的用途 | |
KR0173172B1 (ko) | Crf 길항제로서의 피롤로피리미딘 | |
US8299092B2 (en) | Derivatives of 2-phenyl-3-hydroxyquinoline-4(1H)-one and methods of their preparation and utilization | |
AU2010202009A1 (en) | Quinoxaline compounds | |
IL125076A (en) | Aza compounds, diazole cycloheptane and converted cyclooctane compounds and pharmaceutical preparations containing them | |
FI100530B (fi) | Menetelmä substituoitujen diaminoftaali-imidien ja niiden analogien va lmistamiseksi | |
TWI781607B (zh) | 一種免疫抑制劑、其製備方法和應用 | |
JPH0232058A (ja) | 4―アミノ―3―カルボキシキノリン類およびナフチリジン類、製法および医薬用途 | |
JP4199668B2 (ja) | Sst1アンタゴニスト活性を有するピペラジン誘導体 | |
EP0650964A1 (fr) | Dérivés de 1- 2H-1-benzopyran-2-one-8-yl -pipérazine | |
Snyder et al. | Synthesis of 4-Hydroxyquinolines. VIII. Some Halogen Containing 4-Aminoquinoline Derivatives1 | |
DeWald et al. | Synthesis and Potential Antipsychotic Activity of 1H-Imidazo [1, 2-c] pyrazolo [3, 4-e] pyrimidines | |
EP0093521B1 (fr) | Dérivés de la quinoléine | |
US5804685A (en) | Deazapurine derivatives: a new class of CRF1 specific ligands | |
JPS5838277A (ja) | スピロチアゾリジニルピペラジン誘導体 | |
CS202069B2 (en) | Method of preparing 2-/4-substituted piperazine-1-yl/-4-amino-6,7-dimethoxyquinazolines | |
JP4477010B2 (ja) | タンパク質チロシンホスファターゼ阻害剤としてのジアミノピロロキナゾリン化合物 | |
JPS6229585A (ja) | エーテル化若しくはエステル化しうるジヒドロキシ基により位置2で置換された4―ohキノリンカルボン酸の新規の誘導体、その製造方法、及び医薬としてのその使用 | |
CN105209461A (zh) | 咪唑并吡啶衍生物 | |
Nasr et al. | Synthesis of pyrimido [5, 4-c] quinolines and related quinolines as potential antimalarials | |
CN117486782A (zh) | 一种n-取代咔唑衍生物及其制备方法和应用 | |
CN115340499A (zh) | Bcl-xl抑制剂及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD2A | A request for search or an international type search has been filed | ||
VD1 | Lapsed due to non-payment of the annual fee |
Effective date: 20090401 |